← All trials
NCT07237568
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2025
- Primary completion
- Nov 30, 2026
- Completion date
- Sep 30, 2027
- First posted
- Nov 20, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 352
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lynk Pharmaceuticals Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.